• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • What is ALS/MND
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
      • Open Label Extension
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • AB Science – Masitinib
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • Collaborative Medicinal Development – CuATSM
      • ILB – Tikomed
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Neuronata-R/Lenzumestrocel
      • NeuroSense – PrimeC
      • Neuvivo – NP001
      • Prilenia Therapeutics – Pridopidine
      • T Regulatory Cell Therapies
      • SOD1 Therapies & Trials
    • Approved Drugs
      • Nuedexta
      • Radicava/Edaravone
      • Riluzole/Tiglutik
      • Rozebalamin/Methylcobalamin
      • Tofersen/Qalsody
    • Drugs No Longer in Development
      • Amylyx – AMX0035
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Orphazyme – Arimoclomol
      • TUDCA Trial
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • Diagnostic Delay (in development)
  • Events/Programs
    • Calendar of Events/Programs
    • Alliance Meeting
    • Allied Professionals Forum
    • Alliance Webinars
    • ALS/MND Connect
    • Global Day
    • March of Faces
    • Patient Fellows Program
    • Global CRLI
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Advisory Councils/Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Innovation and Technology Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Archives
      • Newsletters
      • Meetings
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • Members
    • Member Registration
    • Forgot Password

Advocacy Toolkit

What Is Advocacy?

Advocacy is the deliberate process of influencing those who make policy decisions.

In the health, disability and social care sector, advocacy aims to support or encourage an activity that helps people with ALS/MND and their caregivers secure access to health and supportive care to best meet their changing and progressing needs.

Advocacy and influencing at a national level is central to the mission of many ALS/MND associations around the world. Advocacy is a means through which ALS/MND associations ensure that people living with ALS/MND have access to the best possible care within their legal and health and supportive care system.

This resource is designed to help you and your association – whether you are just starting an advocacy program or whether you are looking to expand an existing one. It is also designed to give emerging ALS/MND associations tools they can use to begin engaging in advocacy at the local, regional, national and international level.

Types of Advocacy

A number of different types of advocacy exist. These are 3 main types of advocacy employed by ALS/MND associations and patient advocates around the world: Individual Advocacy, Systemic Advocacy, and Collaborative Advocacy.

Individual Advocacy

Individual advocacy focuses on changing the situation of one person – to protect his or her rights or to improve individual services.

There are two common forms of individual advocacy:

  1. Informal advocacy is undertaken by individuals, their relatives, and friends.
    Many people with ALS/MND and their families have engaged in valuable informal advocacy, but managing ALS/MND can leave little time for the extra effort involved in this process.
  2. Voluntary or nonprofit community-based organisations that advocate for individuals.
    Many ALS/MND associations engage in this type of advocacy. Associations may employ support staff that help individual people with ALS/MND and their families access care and support services locally as needs arise or change. This is an important means of advocacy as care provision systems are often very complex and difficult for individuals to navigate.
    Advocacy also involves educating care providers about the needs of people with ALS/MND to promote access to timely and coordinated multidisciplinary care.

Systemic Advocacy

Systemic advocacy works to change the situations of a whole group of people who share a similar problem, or to change a service system. Systemic advocacy can benefit many people. It also strives to prevent problems before they occur.

Systemic advocacy encourages changes to the law and/or government and service provider policies and community attitudes.

ALS/MND associations may undertake systemic advocacy at the local (state, province, region, territory, etc) or national level within their countries.

Collaborative Advocacy

The fact that the number of people living with ALS/MND is relatively small makes the job of influencing harder – there is power in numbers!

For particular issues, ALS/MND associations may consider engaging in joint advocacy with other groups who have the same or similar needs. These organisations include:

  • Neurological groups
  • Neurodegenerative or neuromuscular disease groups
  • Disability groups
  • Chronic disease/Rare disease alliances
  • Palliative care associations
  • Carer/caregiver associations

What does advocacy do for people with ALS/MND?

Advocacy can:

  • Raise awareness and understanding of ALS/MND and the needs of people with ALS/MND, their families and carers
  • Promote research into ALS/MND
  • Promote positive change to structure and policy, which will be of benefit to people with ALS/MND
  • Help people with ALS/MND and their family to access more resources and better care
  • Help professionals involved in providing services to people with ALS/MND and their families gain access to resources and funding
  • Help people with ALS/MND and their families to access vital support services and make services accountable ensuring there is transparency in their actions and decisions
  • Help people with ALS/MND and their families have control over their situation

What are the requirements for systemic advocacy?

Because systemic advocacy works to cause change in service systems, policy or laws, it requires a long-term, sustained effort. Advocacy also requires:

  • knowledge of how systems, departments and services work, especially with regard to government and health and supportive care departments
  • an understanding of advocacy process and procedures
  • taking opportunities and creating them
  • a sense of urgency
  • doing more than what is routinely done
  • challenging the community
  • engaging with media

Advocacy above all requires that ALS/MND associations know and understand the basic functions of the government and how health, social and supportive care is structured in their country. These questions will be helpful to answer as you get started in advocacy:

  • How is a law made?
  • What are the branches of government, and what is each branch responsible for? Whom should you be advocating to?
  • Who is responsible for allocating resources and how are these decisions made?
  • What are the current government’s policies related to care and support that impact people living with ALS/MND and their families?
  • How do people find their representatives and contact them?

The answers to these questions might change depending on whether you are working at a local or national level.

Common Areas of Advocacy

For Alliance member associations, past and current areas for advocacy might include:

  • Improved clinical care for people with ALS/MND within a given healthcare system
    • Access to multidisciplinary care
    • Access to durable medical equipment
  • Improved support services for people with ALS/MND and their families i.e
    • Access to aids and equipment
    • Home care
    • Disability and/or aged care support
    • Respite care
  • Financial support for people with ALS/MND and their families
  • ALS/MND research funding
  • Increased public awareness and understanding of ALS/MND through official recognition of the disease or related issues

Tips for Successful Advocacy

  • Have clear, realistic goals. If you can, be as specific as possible in your goals. Also consider developing short- and long-term goals and dividing big, general goals into achievable steps.
  • Be strategic and efficient. Try to talk to the right person at the right time to move your policy forward.
  • Develop a campaign or Call to Action to focus on the policy you seek to change
  • Try different tactics. Some possible tactics for contacting policymakers could include:
    • Arrange meetings with relevant politicians and government departments in their offices
    • Engage with the party in power as well as opposition
    • Invite politicians to visit your association or clinic
    • Write letters and make phone calls
    • Use social and traditional media to persuade politicians to champion your call to action
    • Attend town hall meetings or other public events to educate policymakers
  • Encourage grassroots advocates.
    • Identify “grassroots advocates” – people with ALS/MND who support your association and are willing to meet, write letters, email or make phone calls to their local members of Parliament using a script you provide
    • Provide a list of Ministers, Shadow Ministers, representatives or other politicians to support your grassroots advocates
  • Have facts and figures prepared. Find and know relevant statistics. If possible, it might be helpful to undertake surveys or research to produce more figures (for example, a figure for the average cost of living with ALS/MND for one year in your country, or a figure for the average life expectancy of someone with ALS/MND in your country). Present facts and figures in an organized, concise fashion, often through printed handouts or fact sheets.
  • Develop a media/communications plan. Think about how you will communicate your advocacy campaign and engage the public to help or support your advocacy goals, if applicable.
  • Share personal stories. The most persuasive argument is a personal story of someone with ALS/MND who needs help. Of course, an ALS/MND association should always get permission and support from the individual before sharing their story.

Advocacy by ALS/MND associations promotes recognition of the rights and needs of people with ALS/MND and ensures that they have a voice and that it will be heard.

Additional tools from the International Alliance of ALS/MND Associations: Fundamental Rights for People with ALS/MND and Caregivers

Advocacy Success Stories from Alliance Members

ALS Canada: Better financial support for family members caring for a loved one with ALS

Tammy Moore, CEO, ALS Canada celebrates the Compassionate Care Benefit (CCB) increase with ALS Patient Advocate Brian Parson and his wife Susan Robbins Parsons
Tammy Moore, CEO, ALS Canada celebrates the Compassionate Care Benefit (CCB) increase with ALS Patient Advocate Brian Parson and his wife Susan Robbins Parsons

In Canada, an ALS diagnosis can cost a family an estimated $150,000 to $250,000 over the course of the disease, including the costs associated with losing income given that family members must often take time off work to provide care to their loved one.

To help relieve some of this financial burden, ALS Canada and ALS Societies across Canada advocated as part of a collation of health charities for the Government of Canada to extend the Compassionate Care Benefit (CCB) from six to 26 weeks. This benefit provides much needed financial assistance to Canadian families caring for a loved one with a terminal disease.

As of January 3, 2016, Canadian caregivers can now claim up to $13,624 over a 26-week period in benefits, a significant increase from the original entitlement of $3,144 over six weeks. The benefit can also now be taken within an expanded period of 52 weeks and can be shared between family members.

This imperative change is already making a substantial impact on Canadians who are at their most vulnerable financially and emotionally. Through this benefit, families living with ALS can now access a greater level of financial support to help address the debilitating physical effects of this neurodegenerative disease. ALS Canada and ALS Societies across Canada also continue to work with the Government of Canada to improve access to the CCB to ensure this benefit adequately supports caregivers of Canadians living with ALS with every progression of the disease.

MND Australia: 10 years of NDIS influencing - Contributing, collaborating and communicating to ensure early intervention and needs based supports for people living with MND

The idea of a National Disability Insurance Scheme (NDIS) was first introduced at the 2020 Summit held in Canberra in 2008. MND Australia immediately recognised the NDIS as a once in a lifetime opportunity to transform the lives of people living with motor neurone disease (MND).

Aged Care Minister the Hon Ken Wyatt
Carol Birks and David Ali of MND Australia with Aged Care Minister, the Hon. Ken Wyatt (centre)

In 2008 the government established a Disability Care and Support Inquiry to be undertaken by the productivity commission.

Influencing government policy is a long term commitment requiring determination, flexibility and patience.

Over the last 10 years we have worked in partnership with the six state MND Associations with a clear focus to influence the establishment of a scheme that would ensure people living with MND receive the disability supports they need to maintain their independence, social inclusion and quality of life.

From the outset we have worked to contribute, collaborate and communicate to influence the establishment of a scheme that would:

  • Include a diagnosis of MND as one of the early intervention groups
  • Include all people with MND no matter their age or postcode
  • Ensure access to specialised planners who understand the needs of people with complex conditions such as MND
  • and would include an assessment process that would anticipate changing needs

MND Australia contributed to the initial productivity inquiry and contributed to relevant joint submissions and appeared at Productivity Commission hearings and government roundtables to ensure that the voice of people living with MND was loud and strong.

MND Australia welcomed the Productivity Commission report which recognised that the current disability support system should be totally reformed as it was “underfunded, unfair, fragmented, and inefficient, and gives people with a disability little choice and no certainty of access to appropriate supports.”

Following the government decision to establish an NDIS we have continued to write many related submissions and developed position statements to ensure we continued to contribute to the design and development of the scheme.

Collaboration has been a key element of the success in influencing the introduction of the NDIS.

Disability organisations representing myriad disabilities and conditions have been relentless in their advocacy with many coming together to form alliances and collaborations. As a founding member of the Neurological Alliance Australia we have worked to develop joint position statements, and submissions to strengthen our collective advocacy.

MND community at the Neurological Alliance meeting 2017
The MND community at the Neurological Alliance Meeting, 2017

A special briefing held in 2017 at Parliament House provided the opportunity to  highlight our joint position on the development of the NDIS and to highlight the need for improved pre-planning support, NDIS planning sessions that recognise the unique needs of people with a progressive neurodegenerative condition and the mandatory inclusion of Coordination of Support for his cohort.

Since the NDIS was established the MND associations have endeavoured to collaborate with National Disability Insurance Agency – NDIA – staff at the grassroots level as well as federally.

The NDIS started as a trial in July 2013 in sites in NSW and Victoria and the MND Associations in those States have been actively involved from the outset – advocating for individuals, educating local NDIA staff, working with existing multidisciplinary teams; and working to improve NDIA understanding of MND, within a model focused on capacity building.

The introduction of a new scheme of this magnitude is challenging, frustrating and confusing for everyone.

Learnings from the trial sites informed our work to develop a ‘starter plan’ – the first of its kind. The aim was to support planners to understand the complex and progressing nature of MND and to minimise the need for repeated plan reviews. This led to the development of the NDIA Practice Guide for MND which was the first disease specific practice guide to be developed and adopted by the NDIA.

Over the last 10 years we have communicated with relevant Ministers, Opposition Spokespeople and federal politicians. We have endeavored to provide solid evidence wherever we can to influence and to communicate the impact of the NDIS on people living with MND, and to highlight gaps and issues faced by individuals.

We have focused on communicating and sharing experiences, frustrations and highlights with each other through NDIS discussions at every CEO, board and national support service staff meetings. This has facilitated and supported changes to MND association service delivery and helped us respond to changing goal posts and funding models as the NDIS has rolled out nationally.

Importantly the state based associations have worked to communicate with their members, people living with MND, to ensure they have access to the information and support they need as they transition to the NDIS.

Representatives from the State Associations of Victoria and NSW with then-Minister for Disability Services, the Hon. Mitch Fifield

The MND community, people living with MND and their families and the specialist MND multidisciplinary clinics and services have also been key to influencing the development of the NDIS. A number of MND Week campaigns have focused on the NDIS, engaging the community in highlighting the need for the right care at the right time in the right place.

Sharing personal stories at Parliamentary events and meetings with politicians of all persuasions has been integral to informing the debate and the development of the scheme. And of course it is the personal stories that engage the media and help to highlight particular issues that people face in trying to get plans in place to meet their individual and reasonable and necessary support needs.

So are we there yet? MND was identified as an early intervention group and some NDIS participants living with MND have received plans that are having positive, life-changing impacts on their lives; many others however, struggle to receive plans that take their progressing and complex needs into account.

Unfortunately fairly early on it was evident that people living with MND diagnosed when aged 65 or older would not be eligible. Our focus has been to keep advocating strongly to include this cohort and to meanwhile influence the aged care sector to provide individualised needs based supports for older Australians with MND.

Our collective influencing must therefore continue to ensure access to needs based disability supports for all Australians with MND whether funded by the NDIS or the Aged Care sector. We will continue to work closely with the people living with MND and their families to provide individualised grassroots advocacy and individual case studies will continue to be gathered and provided to the NDIA and the to the Aged Care Minister to strengthen and support influencing nationally.

Primary Sidebar

Advocacy

  • Advocacy Toolkit

  • John and Loretta Russo, USA

    John and Loretta Russo, USA
    final3878

  • Marcel R. Wernard, Diagnosed 2016,  ALS Patients Connected,  The Netherlands

    Marcel R. Wernard, Diagnosed 2016, ALS Patients Connected, The Netherlands

  • Ali Var, Turkey

    Ali Var, Turkey

  • Dick Dayton, USA

    Dick Dayton, USA

  • Luis Antonio Pimenta Lima, Brazil

    Luis Antonio Pimenta Lima, Brazil

  • Kris Van Reusel, Belgium

    Kris Van Reusel, Belgium

  • John Dinon, MND Australia

    John Dinon, MND Australia

  • João Marcos Andrietta, Diagnosed 2008 , ABrELA, Brazil

    João Marcos Andrietta, Diagnosed 2008 , ABrELA, Brazil

  • Mark Miller

    Mark Miller

  • Glen Elison,  ALS Hope Foundation,  Diagnosed 2019,  USA

    Glen Elison, ALS Hope Foundation, Diagnosed 2019, USA

  • Teddy Hanono Annie, Apoyo Integral Gila A.C., Diagnosed 2018, Mexico

    Teddy Hanono Annie, Apoyo Integral Gila A.C., Diagnosed 2018, Mexico

  • Conny van der Meijden, Diagnosed 2001,  ALS Netherlands

    Conny van der Meijden, Diagnosed 2001, ALS Netherlands

  • Claudia Cominetti, Associazione conSLAncio Onlus,  Italy

    Claudia Cominetti, Associazione conSLAncio Onlus, Italy

  • Leon Ryba, Argentina

    Leon Ryba, Argentina

  • Joy Blakeley, Diagnosed 2017 , MND Australia

    Joy Blakeley, Diagnosed 2017 , MND Australia

  • Mike Small, Motor Neurone Disease (MND) Association, UK

    Mike Small, Motor Neurone Disease (MND) Association, UK

  • Joyce Rusinak, Forbes Norris ALS Center, USA

    Joyce Rusinak, Forbes Norris ALS Center, USA

  • Mauril Belanger

    Mauril Belanger

  • Lin Yong Yi, Taiwan MND Association, Diagnosed 2004

    Lin Yong Yi, Taiwan MND Association, Diagnosed 2004

  • Osiel Mendoza, Diagnosed 2016 ,  ALS Therapy Development Institute, USA

    Osiel Mendoza, Diagnosed 2016 , ALS Therapy Development Institute, USA

  • Yessenia Hernandez Mendoza, Apoyo Integral Gila A.C., Diagnosed 2018, Mexico

    Yessenia Hernandez Mendoza, Apoyo Integral Gila A.C., Diagnosed 2018, Mexico

  • Marco Antonio Alvarez Mercado, Mexico

    Marco Antonio Alvarez Mercado, Mexico

  • Jan Zuring, Diagnosed 2010 , The Netherlands

    Jan Zuring, Diagnosed 2010 , The Netherlands

  • Lachlan Terry,  MND Australia,  Diagnosed 2015

    Lachlan Terry, MND Australia, Diagnosed 2015

  • Fernando Ocampo Cardona, Colombia

    Fernando Ocampo Cardona, Colombia

  • Mauril Bélanger, Diagnosed 2015 , ALS Canada

    Mauril Bélanger, Diagnosed 2015 , ALS Canada

  • Maurice Leclerc, Canada

    Maurice Leclerc, Canada

  • Valdomiro Xavier Honório, Brazil

    Valdomiro Xavier Honório, Brazil

  • Enzo Maccarrone, AISLA ONLUS, Italy

    Enzo Maccarrone, AISLA ONLUS, Italy

  • Fabio Carvalho, Associação Pró-Cura da ELA, Brazil

    Fabio Carvalho, Associação Pró-Cura da ELA, Brazil

  • Shera Mukherjee, Diagnosed 2013,  Asha Ek Hope Foundation, India

    Shera Mukherjee, Diagnosed 2013, Asha Ek Hope Foundation, India

  • Ian Gale, MND Australia

    Ian Gale, MND Australia

  • Mary Thomas, Diagnosed 2013 , MND Australia

    Mary Thomas, Diagnosed 2013 , MND Australia

  • Ian Roberts

    Ian Roberts

  • Hans Dieter Olszewski, Diagnosed 2010 , DGM, Germany

    Hans Dieter Olszewski, Diagnosed 2010 , DGM, Germany

  • Claudia Gotti, Brazil

    Claudia Gotti, Brazil

  • Oliver Juenke, DGM, Germany

    Oliver Juenke, DGM, Germany

  • Xian-Zhang Niu, Diagnosed 2006 , Shaanxi ALS Association, China

    Xian-Zhang Niu, Diagnosed 2006 , Shaanxi ALS Association, China

  • Dawn Morton, Diagnosed 2014 , MND Scotland, UK

    Dawn Morton, Diagnosed 2014 , MND Scotland, UK

  • Jette Odgaard Villemoes, Muskelsvindfonden, Denmark

    Jette Odgaard Villemoes, Muskelsvindfonden, Denmark

  • Calum Ferguson, Diagnosed 2010 , MND Scotland, UK

    Calum Ferguson, Diagnosed 2010 , MND Scotland, UK

  • Amparo Muriel Engativa, Colombia

    Amparo Muriel Engativa, Colombia

  • Camilla Heiberg Freiberg, Muskelsvindfonden, Denmark

    Camilla Heiberg Freiberg, Muskelsvindfonden, Denmark

  • Carlos Alberto Báez Murillo, ACELA, Colombia

    Carlos Alberto Báez Murillo, ACELA, Colombia

  • Wiebke Braach, Deutsche Gesellschaft für Muskelkranke, Germany

    Wiebke Braach, Deutsche Gesellschaft für Muskelkranke, Germany

  • Sharon Corosanite, Diagnosed 2014 , ALS Hope Foundation, USA

    Sharon Corosanite, Diagnosed 2014 , ALS Hope Foundation, USA

  • Danny Reviers, Diagnosed 1979 , ALS Liga België, Belgium

    Danny Reviers, Diagnosed 1979 , ALS Liga België, Belgium

  • Chun Ju Xiao, China

    Chun Ju Xiao, China

  • Emilienne Verhaegen, ALS Liga Belgium, Diagnosed 2014

    Emilienne Verhaegen, ALS Liga Belgium, Diagnosed 2014

  • Soledad Rodriguez, FUNDELA, Diagnosed 2013, Spain

    Soledad Rodriguez, FUNDELA, Diagnosed 2013, Spain

Learn more about the March of Faces

Latest Tweets

  • Just now

Footer

Subscribe to our Bi-Monthly Newsletter

Sign up to receive updates and to hear what's going on in the International Alliance of ALS/MND Associations.

"*" indicates required fields

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2025 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login